- Home
- Equipment
- usa new york
- t standard polystyrene disposable cell
Show results for
Refine by
T Standard Polystyrene Disposable Cell Equipment Supplied In Usa New York
32 equipment items found
Manufactured by:Creative Peptides based inNew York, NEW YORK (USA)
Thymopentin, also known as TP-5, is a synthetic derivative of thymopoietin, a thymic hormone, and has immunoregulatory properties. Thymopentin interacts with T cells, reduces endocrine and behavioral responses to experimental stress. It is also found to increase the number of cells undergoing apoptosis in irradiated cells and selectively bind to apoptotic ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-400, our DeltEx Allo DRI, is a preclinical product candidate expanding the application of DRI gamma-delta T cells into other solid tumor types through the development of allogeneic or “off-the-shelf” DeltEx DRI therapy. We aim to take the clinical results from the ongoing INB-200 and INB-100 clinical trials to provide the safety data to support an IND submission for INB-400. The ...
Manufactured by:Creative Peptides based inNew York, NEW YORK (USA)
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been ...
Manufactured by:Profacgen based inShirley, NEW YORK (USA)
Recombinant Cynomolgus PDCD1 Protein (B0LAJ3) (Leu 25 - Gln 167) with a polyhistidine tag at the C-terminus was expressed in ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
elociT™ is our unique mouse technology for producing fully human therapeutic T-cell receptors (TCR) against tumor and viral antigens. Regeneron uses this technology as part of its efforts to discover and develop novel immuno-oncology therapeutic candidates, including combination approaches and to assist our collaborators in producing fully human therapeutic ...
Manufactured by:UroGen Pharma, Inc. based inPrinceton, NEW YORK (USA)
UroGen is evaluating UGN-301, our in-licensed anti-CTLA-4 antibody (zalifrelimab), as a monotherapy and as combination therapy with ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-200, our DeltEx DRI, is a genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors. This is the first genetically engineered gamma-delta T cell therapy to be administered to patients and our initial indication is newly diagnosed Glioblastoma (GBM). Since 2005 the standard of care treatment for GBM has been surgical resection followed by radiation ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed on tumor cells, and (ii) short hairpin RNA (shRNA) technology to knockdown the expression of NKG2D ligands MICA ...
Manufactured by:Adaptive Biotechnologies based inSeattle, WASHINGTON (USA)
Our TCR-antigen discovery capabilities may inform the design and development of next-generation vaccines. Adaptive has validated hundreds of immunogenic antigens that can be selected to design differentiated vaccines. Our platform is also used to detect and track vaccine-induced antigen-specific T cell responses that correlate with efficacy and safety. Our antigen specificity ...
Manufactured by:Thermo Fisher Scientific based inWaltham, MASSACHUSETTS (USA)
Invitrogen TrueCut HiFi Cas9 Protein is a high fidelity CRISPR Cas9 protein variant engineered to demonstrate superior off-target profiles, while preserving maximum on-target editing efficiency. TrueCut HiFi Cas9 Protein is ideal for applications that are sensitive to off-target events and when more precise editing is ...
Manufactured by:Taconic Biosciences, Inc. based inRensselaer, NEW YORK (USA)
The Abb mouse was developed in the laboratory of Michael J. Grusby et al. of the Harvard School of Public Health. The model was created by targeting the H2-Ab1 gene in ES-D3 cells and injecting the targeted ES cells into C57BL/6 blastocysts. Resultant chimeras were backcrossed to C57BL/6 for 4 generations (N4). Taconic received stock from Tufts University in December 1991, and the mice were ...
Manufactured by:Creative BioMart based in, NEW YORK (USA)
Interleukin-4, is a cytokine that induces differentiation of naive helper T cells (Th0 cells to Th2 cells). In the presence of IL-4 and IL-13, cytokines that are produced in a Th-2 type response, particularly during allergy and parasitic infections, macrophages become differentially activated, And this cytokine is a ligand for interleukin 4 receptor. The interleukin 4 receptor also binds to IL13, ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-300, our DeltEx DRI CAR-T, is a preclinical product candidate combining our expertise in gamma-delta T cells, our DRI technology and a novel CAR-directed against the Cholotoxin peptide. Chlorotoxin binds to GBM tumor cells and has been previously utilized as a tumor paint in this setting. Chlorotoxin can also bind to other solid tumors including lung, breast and prostate cancers, among ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-203 is a preclinical, non-gene edited allogeneic CAR T candidate and our first armored CAR T candidate engineered to co-express the cytokine interleukin-18 (IL-18) with the NKG2D CAR receptor. IL-18 is a proinflammatory cytokine that directly potentiates the anti-cancer activity of CAR T cells while also altering the balance of pro- and anti-inflammatory cells within tumor tissue. CYAD-203 ...
Manufactured by:Creative BioMart based in, NEW YORK (USA)
IL-4 is a pleiotropic cytokine that regulates diverse T and B cell responses including cell proliferation, survival and gene expression. Produced by mast cells, T cells and bone marrow stromal cells, IL-4 regulates the differentiation of naive CD4+ T cells into helper Th2 cells, characterized by their cytokine-secretion profile that includes secretion of IL-4, IL-5, IL-6, IL-10, and IL-13, which ...
Manufactured by:Adaptive Biotechnologies based inSeattle, WASHINGTON (USA)
We are currently leveraging our TCR discovery capabilities to enable commercialization of novel therapies by collaborators. In the future, we may explore expanding our end-to-end capabilities for the development of cellular therapies and vaccines. TruTCR is summarized in the figure ...
by:Hookipa Pharma Inc. based inVienna, AUSTRIA
Our scientific platform includes two distinct approaches to arenavirus-based therapies: replicating and non-replicating. Our replicating technology is designed to create a stronger immune response that we believe is more appropriate for use in oncology. Our non-replicating technology is designed to evoke a potent immune response for prophylactic use against infectious disease. ...
Manufactured by:Taconic Biosciences, Inc. based inRensselaer, NEW YORK (USA)
In order to selectively inactivate genes in a tissue specific manner many laboratories have developed Cre transgenic mouse strains in which the Cre recombinase is expressed under the control of a tissue specific promoter. The Lck-Cre transgenic mouse uses the proximal promoter of the Lck (lymphocyte protein tyrosine kinase) gene, which is first expressed early in thymocyte development at the ...
Manufactured by:ENB Therapeutics based inNew York, NEW YORK (USA)
ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers restore ICAM-1 expression which is required for T-cells to leave the circulation and infiltrate the tumor. Activated T cells are then able to infiltrate the tumor and kill ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-701 is an immunotherapy designed to direct the immune system to attack targets present on certain malignancies including brain cancer. SL-701 comprises 3 short synthetic peptides that correspond to epitopes of targets including IL-13Rα2, EphA2, and survivin; 2 of these synthetic peptides (IL-13Rα2 and survivin) are mutant and believed to enhance immune activity. A multicenter Phase ...